These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19546817)

  • 1. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer.
    Qi Y; Schild SE; Mandrekar SJ; Tan AD; Krook JE; Rowland KM; Garces YI; Soori GS; Adjei AA; Sloan JA
    J Thorac Oncol; 2009 Sep; 4(9):1075-82. PubMed ID: 19546817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between deficits in overall quality of life and non-small-cell lung cancer survival.
    Sloan JA; Zhao X; Novotny PJ; Wampfler J; Garces Y; Clark MM; Yang P
    J Clin Oncol; 2012 May; 30(13):1498-504. PubMed ID: 22454418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
    Movsas B; Moughan J; Sarna L; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Wasserman T; Bruner DW
    J Clin Oncol; 2009 Dec; 27(34):5816-22. PubMed ID: 19858383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials.
    Huschka MM; Mandrekar SJ; Schaefer PL; Jett JR; Sloan JA
    Cancer; 2007 Feb; 109(4):787-95. PubMed ID: 17211864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.
    Fiteni F; Vernerey D; Bonnetain F; Vaylet F; Sennélart H; Trédaniel J; Moro-Sibilot D; Herman D; Laizé H; Masson P; Derollez M; Clément-Duchêne C; Milleron B; Morin F; Zalcman G; Quoix E; Westeel V
    Eur J Cancer; 2016 Jan; 52():120-8. PubMed ID: 26682871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy.
    Langendijk H; Aaronson NK; de Jong JM; ten Velde GP; Muller MJ; Wouters M
    Radiother Oncol; 2000 Apr; 55(1):19-25. PubMed ID: 10788684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.
    J Natl Cancer Inst; 1999 Jan; 91(1):66-72. PubMed ID: 9890172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study.
    Yang P; Mandrekar SJ; Hillman SH; Allen Ziegler KL; Sun Z; Wampfler JA; Cunningham JM; Sloan JA; Adjei AA; Perez E; Jett JR
    J Thorac Oncol; 2009 Apr; 4(4):479-85. PubMed ID: 19347979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
    Mandrekar SJ; Schild SE; Hillman SL; Allen KL; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Chansky K; Kelly K; Adjei AA; Jett JR
    Cancer; 2006 Aug; 107(4):781-92. PubMed ID: 16847887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of anemia on chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer].
    Xu C; Gao Y; Li L; Xing L; Liu S
    Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):968-74. PubMed ID: 20959070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers.
    Xie D; Allen MS; Marks R; Jiang G; Sun Z; Nichols F; Zhang M; Chen C; Aubry MC; Jatoi A; Garces YI; Mansfield A; Wigle D; Molina J; Deschamps C; Yang P
    Eur J Cardiothorac Surg; 2018 Jun; 53(6):1214-1222. PubMed ID: 29293957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
    Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
    PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group.
    Firat S; Byhardt RW; Gore E
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):357-64. PubMed ID: 12243808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of pretreatment albumin-to-alkaline phosphatase ratio for overall survival for patients with advanced non-small cell lung cancer.
    Zhou S; Jiang W; Wang H; Wei N; Yu Q
    Cancer Med; 2020 Sep; 9(17):6268-6280. PubMed ID: 32691996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
    Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
    JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
    Groen HJ; Sietsma H; Vincent A; Hochstenbag MM; van Putten JW; van den Berg A; Dalesio O; Biesma B; Smit HJ; Termeer A; Hiltermann TJ; van den Borne BE; Schramel FM
    J Clin Oncol; 2011 Nov; 29(32):4320-6. PubMed ID: 21990410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
    Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
    J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in stage III non-small-cell lung cancer.
    Ademuyiwa FO; Johnson CS; White AS; Breen TE; Harvey J; Neubauer M; Hanna NH
    Clin Lung Cancer; 2007 Sep; 8(8):478-82. PubMed ID: 17922971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.